These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 20890863

  • 1. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 2. The androgen receptor for the radiation oncologist.
    Quero L, Rozet F, Beuzeboc P, Hennequin C.
    Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
    [Abstract] [Full Text] [Related]

  • 3. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 4. [Pathophysiology and therapy of castration-resistant prostate cancer].
    Merseburger AS, Kuczyk MA, Wolff JM.
    Urologe A; 2013 Feb 29; 52(2):219-25. PubMed ID: 23160609
    [Abstract] [Full Text] [Related]

  • 5. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Feb 29; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 6. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002 Feb 29; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

  • 7. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 29; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 8. Innovations in the systemic therapy of prostate cancer.
    Shepard DR, Raghavan D.
    Nat Rev Clin Oncol; 2010 Jan 29; 7(1):13-21. PubMed ID: 19997075
    [Abstract] [Full Text] [Related]

  • 9. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998 Jan 29; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 10. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ, Small EJ.
    Urology; 2003 Dec 29; 62 Suppl 1():87-94. PubMed ID: 14747046
    [Abstract] [Full Text] [Related]

  • 11. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
    Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D.
    Eur J Nucl Med Mol Imaging; 2020 Jan 29; 47(1):9-15. PubMed ID: 31654093
    [No Abstract] [Full Text] [Related]

  • 12. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF, Lee WR.
    Arch Esp Urol; 2011 Oct 29; 64(8):858-64. PubMed ID: 22052767
    [Abstract] [Full Text] [Related]

  • 13. [Castration resistant prostate cancer 2011].
    Miller K.
    Aktuelle Urol; 2011 Mar 29; 42(2):95-102. PubMed ID: 21437832
    [Abstract] [Full Text] [Related]

  • 14. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO, Crawford ED.
    Curr Opin Urol; 2013 May 29; 23(3):208-13. PubMed ID: 23492838
    [Abstract] [Full Text] [Related]

  • 15. Recent advances in hormonal therapy for advanced prostate cancer.
    Oottamasathien S, Crawford ED.
    Oncology (Williston Park); 2003 Aug 29; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
    [Abstract] [Full Text] [Related]

  • 16. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
    Labrie F.
    J Steroid Biochem Mol Biol; 2015 Jan 29; 145():144-56. PubMed ID: 24925260
    [Abstract] [Full Text] [Related]

  • 17. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul 29; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul 29; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 19. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Jul 29; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 20. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A.
    Arch Esp Urol; 2002 Sep 29; 55(7):771-5. PubMed ID: 12380304
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.